Immunoprecise Antibodies Ltd (IPA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunoprecise Antibodies Ltd (IPA) has a cash flow conversion efficiency ratio of -0.048x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($23.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immunoprecise Antibodies Ltd net asset quality index to measure how much of total assets are equity-financed.
Immunoprecise Antibodies Ltd - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Immunoprecise Antibodies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IPA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Immunoprecise Antibodies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunoprecise Antibodies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Data Communications Management Ltd
TO:DCM
|
0.347x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Stella Holdings Bhd
KLSE:5006
|
-0.011x |
|
Marvipol S.A.
WAR:MVP
|
0.015x |
|
Investeringsselskabet Luxor A/S
CO:LUXOR-B
|
0.030x |
|
Trans Power Marine Tbk
JK:TPMA
|
0.067x |
|
Yiren Digital Ltd
F:19YA
|
0.040x |
|
KGL Resources Ltd
AU:KGL
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Immunoprecise Antibodies Ltd (1997–2025)
The table below shows the annual cash flow conversion efficiency of Immunoprecise Antibodies Ltd from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Immunoprecise Antibodies Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -160.37% |
| 2022-04-30 | $75.28 Million | $-9.92 Million | -0.132x | -1150.23% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +318.14% |
| 2011-04-30 | $158.40K | $-80.39K | -0.507x | -793.11% |
| 2010-04-30 | $5.43 Million | $-308.49K | -0.057x | -147.62% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -86.65% |
| 2007-04-30 | $5.43 Million | $-297.31K | -0.055x | -93.48% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +33.99% |
| 2003-04-30 | $867.54K | $-168.38K | -0.194x | +52.10% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more